Humacyte Inc
NASDAQ:HUMA

Watchlist Manager
Humacyte Inc Logo
Humacyte Inc
NASDAQ:HUMA
Watchlist
Price: 0.975 USD 1.56% Market Closed
Market Cap: 182.6m USD

Operating Margin
Humacyte Inc

-6 702.8%
Current
-28 471%
Average
-4.3%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-6 702.8%
=
Operating Profit
-105.3m
/
Revenue
1.6m

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
US
Humacyte Inc
NASDAQ:HUMA
182.6m USD
-6 703%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-17 527%
US
Abbvie Inc
NYSE:ABBV
405.3B USD
33%
US
Amgen Inc
NASDAQ:AMGN
176.3B USD
34%
US
Gilead Sciences Inc
NASDAQ:GILD
151B USD
39%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
114.8B USD
39%
US
Epizyme Inc
F:EPE
94.1B EUR
-370%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
81.7B USD
28%
AU
CSL Ltd
ASX:CSL
83.3B AUD
26%
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
52.7B USD
8%
NL
argenx SE
XBRU:ARGX
44.3B EUR
22%
No Stocks Found

Humacyte Inc
Glance View

Market Cap
182.6m USD
Industry
Biotechnology

Humacyte, Inc. engages in the manufacture of human acellular matrix products for vascular and non-vascular applications. The company is headquartered in Durham, North Carolina and currently employs 145 full-time employees. The company went IPO on 2020-09-22. The company is developing a portfolio of human acellular vessels (HAVs) with varying diameters and lengths. The HAV cabinet would initially target the vascular repair, reconstruction and replacement market, including vascular trauma; atrioventricular (AV) access for hemodialysis; peripheral arterial disease (PAD); and coronary artery bypass grafting (CABG). The firm has developed a paradigm for manufacturing human tissues that is intended to mimic key aspects of human physiology. The company is developing and manufacturing acellular tissues to address life- and limb-threatening vascular conditions while focusing on potential future applications for complex tissue and organ diseases. The company is also engaged in developing its HAVs for pediatric heart surgery and the delivery of cellular therapies, including pancreatic islet cell transplantation to treat Type 1 diabetes.

HUMA Intrinsic Value
Not Available
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-6 702.8%
=
Operating Profit
-105.3m
/
Revenue
1.6m
What is the Operating Margin of Humacyte Inc?

Based on Humacyte Inc's most recent financial statements, the company has Operating Margin of -6 702.8%.

Back to Top